Cargando…
Resistance to chemoimmunotherapy in non-small-cell lung cancer
Recent clinical trials evaluating the combination of chemotherapy with immune checkpoint inhibition for the primary treatment of lung cancer showed increased progression-free and overall survival compared with chemotherapy alone. However, the combination of these two modalities is less than additive...
Autor principal: | Hochmair, Maximilian Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992480/ https://www.ncbi.nlm.nih.gov/pubmed/35582443 http://dx.doi.org/10.20517/cdr.2020.09 |
Ejemplares similares
-
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
por: Hochmair, Maximilian
Publicado: (2018) -
Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer
por: Kurono, Yuri, et al.
Publicado: (2020) -
Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2020) -
Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021) -
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)